Replimune Inc. (REPL): Rasio utang jangka dawa marang modal

Replimune Group, Inc. (REPL) is currently undergoing clinical trials, aiming to outperform global leaders in treatment efficacy. Meanwhile, cross-border research between the US and Britain is subject to risks stemming from sanctions and patent disputes. This trading chart featuring the 1.02 metric complements the analysis of a business focused on developing modified viruses to destroy solid tumors and activate the body's immune defenses.

This ratio measures the proportion of long-term liabilities within the equity structure, determining the level of financial stability and the company's reliance on external debt financing. By analyzing the long-term debt-to-equity ratio, an investor can assess the ability of Replimune Group, Inc. (REPL) to fund expensive late-stage clinical trials of oncolytic viruses without a critical risk of insolvency.